Presto Engineering Announces Leadership Change
16.1.2023 11:00:00 EET | Business Wire | Press release
Presto Engineering, the recognized microelectronics expert from ASIC design to semiconductor production services, announces a strengthening of its leadership to support its aggressive strategic plan of future growth. Cédric Mayor, VP Global Strategy & Corporate Development, is appointed Chief Executive Officer (CEO) of the company. Previous CEO, and company founder, Michel Villemain, is appointed Executive Chairman, primarily focusing on strategic and corporate development. The change is effective January 11, 2023, and is the result of a year-long transition process initiated by the company’s leadership.
“As a member of the core management team of Presto, Cédric has played a key role in the development of the company over the years, and I am glad that he is stepping up to CEO,” said Thomas Fort, Chairman of the company’s Supervisory Board. “I would also like to thank Michel Villemain for his vision and strong leadership over the years, and I am delighted that Michel is staying on as Executive Chairman. I am looking forward to working with both Cédric and Michel in their new roles.”
“Presto Engineering has come a long way since 2006, when we started it with Frank Sauk in California,” said Michel Villemain. “In the past 16 years, we have established a market leader and created the foundation for further expansion. I wish Cédric all the best in driving the company forward, after all we have done together for Presto since 2009. I want to thank our team—and all who have contributed to Presto’s achievements over the years—for their dedication and efforts and our shareholders for their confidence and support. I look forward to participating in our continued success in this more strategic role.”
“I feel honored to be appointed as the next CEO of Presto Engineering, and together with our extremely talented colleagues, will continue to help our customers create their products through semiconductor innovations and passion,” said Cédric Mayor, incoming CEO of Presto Engineering. “I wish to thank Michel Villemain for this amazing 13-year journey we shared together while continuing working with him in his new role, as well as to the Supervisory Board for their confidence. I look forward to shaping the next chapter of Presto Engineering, while empowering our team to deliver outstanding service and support that exceeds our customers’ expectations.”
Cédric Mayor has more than 23 years of experience in the semiconductor business, which includes 13 years at Presto Engineering across various executive management positions. Cédric has held several technical and executive management roles at NXP Semiconductors, from process release to front-end and back-end of line migration, as part of the asset light company vision. Cédric started his career with SOISIC (a start-up acquired by Arm) as lead architect of silicon embedded memory and compilers. Cédric graduated from Ecole Centrale Marseille in France; he holds an MS in Physics & Electrical Engineering, with several patents and papers in the field.
About Presto Engineering
Presto Engineering provides ASIC design and outsourced operations for semiconductor and IoT device companies, helping its customers minimize overhead, reduce risk, and accelerate time-to-market. The company is a recognized expert in the development of industrial solutions for RF, analog, mixed-signal, and secured applications―from design, tape-out, to delivery of finished goods. Presto’s proprietary, highly secure manufacturing and provisioning solution, coupled with extensive back-end expertise, gives its customers a competitive advantage. The company offers a global, flexible, dedicated framework, with headquarters in Meyreuil, France, and operations across Europe, North America, and Asia. For more information, visit: www.presto-eng.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005105/en/
Contact information
Presto Engineering Company Contact:
Matyas Schegerin
+33 7 79 94 49 21
matyas.schegerin@presto-eng.com
Media Contact for Presto Engineering:
Sandy Fewkes
+1 408 529 9685
SandyLFewkes@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom